Zusammenfassung
Die Möglichkeit, den Eintritt einer Schwangerschaft zeitlich zu bestimmen bzw. die Konzeptionsmöglichkeit zu regulieren, ist sicherlich eine der wesentlichsten gesellschaftlichen Entwicklungen des 20. Jahrhunderts gewesen. Kaum eine andere Entwicklung wird gesellschaftliche Strukturen und soziale Verhaltensweisen mehr beeinflusst haben. Die Altersstruktur der deutschen Bevölkerung veranschaulicht ◘Abb. 13.1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
AG Hormone des BVF (2006) Empfehlungen zur Notfallkontrazeption mit Levonorgestrel für Ärzte im Notdienst. Frauenarzt 47 12: 1093–93
Anonymous (2000) Hormonbedingtes Mammakarzinom-Wachstum. Sind die Gestagene das Problem? Gyne Z Frauenarzt 3: 72
Beerthuizen R, van Beek A, Massai R, Mäkäräinen L, in't Hout J, Coelingh- Bennink HJ (2000) Bone mineral density during longterm use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 15: 118–122
Birkhäuser M, Braendle W, Kellet PJ et al. (2006) Krebsrisiko und Dosisreduktion bei Ovulationshemmern. Frauenarzt 47 12: 1105–1108
Bishop E, Nelms WF (1930): A simple method of tubal sterilization. NY State J Med 39: 214
Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP (2000) Higher risk of venous thrombosis during early use of oral contraceptives on woman with inherited clotting defects. Arch Intern Med 160: 49–52
Chiafferino F, Parazzi F, La Vecchacia C (1999) Use of oral contraceptives and intrauterine fibroids from a case control study. Brit J Obstet Gynecol 106: 857–860
Croxatto HB, Mäkäräinen L (1998) Pharmakodynamik und Wirksamkeit von Implanon. Contaception 58: 91S–97S
Croxatto HB, Urbancsek J, Massai R, Coelingh BH, van Beek A (1999) A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 14: 976–981
Dorn C, Hugo U, Grave C (2009) Kontrazeption – individuelle Anpassung, XXI. Intensivkurs Gynäkologische Endokrinilogie und Reproduktionsmedizin, UK-SH Schleswig-Holstein/Endokrinologikum, Hamburg
Dramusic V, Goh VH, Rajan U et al. (1997) Clinical, endocrinologic and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. J Pediatr Adolesc Gynecol 10: 125–132
Dunson DB, Baird DD, Wilcox AJ, Weinberg CR (1999) Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Hum Reprod 14: 1835–1839
Ellertson C (2000) Contraceptive choice. In: Glasier A, Gebbie AE (eds) Handbook of family planning and reproductive healthcare. Churchill Livingstone, London
Ellertson C, Evans M, Ferden S et al. (2003) Extending the time limit for starting the yuzpe regimen of emergency contraception to 120 hours. Obstet Gynecol 101: 1168–1171
Farmer RDT, Lawrenson RA (1998) Oral contraceptives and venous thromboembolic disease: The findings from database studies in the United Kongdom and Germany. Am J Obstet Gynacol 179: 78–86
Farmer RDT, Lawrenson RA, Thompson JG, Hambleton IR (1997) Population- based study of risk of venous thromboembolism associated with varous oral contraceptives. Lancet 349: 83–88
Findlay JK (1996) Future direction for research on endometrial bleeding. Human Reprod 11 (Suppl 2): 179–183
Franceshi S, La Vecchia C (1998) Colorectal cancer and hormone replacement therapie: unexpected finding. Eur J Cancer Prev 7: 427–438
Garbe E, Heinemann LAJ, Rabe T, Winkler UH (2000) Nicht-kontrazeptiver Nutzen der Pille – ein oft unbeachteter Fakt. Zentralbl Gynakol 122: 18–274
Glasier AF, Smith KB, van der Spuy ZM et al. (2003) Amenorrhea associated with contraception: an international study on acceptability. Contraception 67: 1–8
Göretzlehner G, Ahrendt H-J, Brucker C (2004) Langzyklus und Langzeiteinnahme. Eine neue Form der oralen hormonalen Kontrazeption? Frauenarzt 45: 199–203
Göretzlehner G, Lauritzen Ch, Göretzlehner U (2007) Praktische Hormontherapie in der Gynäkologie. Berlin: De Gruyter
Grigorieva V, Chen-Mok M, Turasova M et al. (2003) Use of a levonorgestrel- releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 79: 1194–1198
Grimes DA (2000) Intrauterine device and upper-genital-tract infection. Lancet 356: 1013–1019
Gruber DM, Huber JC, Melis GB, Stagg C, Parke S, Marr J (2006) A comparison of the cycle control, safety, and efficacy profile of a 21- day regimen of ethinylestradiol 20 mug and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 mug and desogestrel 150 mug. Treat Endocrinol. 5 (2): 115–121 [PubMed PMID: 16542051]
Haberlandt L (1924) Über hormonale Sterilisierung weiblicher Tiere. II. Mitteilung (Injectionsversuche mit Corpus-Luteum, Ovarialund Placentaopton). Pflügers Arch Gesamte Physiol 200: 1–13
Halstrick C (2005) Juristische Aspekte der Mädchensprechstunde: Verordnung von Kontrazeptiva, Frauenarzt 46: 660–663
Kadir RA, Lukas AS, Kouides PA et al. (2005) Management of excessive bleeding in women with haemostatic disorders. Fertil Steril 84: 1352–1359
Kay CR (1984) Royal College of General Practitioner's oral contraception study. Clin Obstet Gynecol 11: 1018–1022
Khader YS, Rice J, John L et al. (2003) Oral contraceptives and the risc of myocardial infarction: a meta-analysis. Contraception 68: 11–17
Kingman CEC, Kadir RA, Lee CA et al. (2004) The use of levonorgestrelreleasing intrauterine-system for treatment of menorrhagia in women with inhelited bleeding disorders. Int J Obstet Gynecol 11: 1425–1428
Kirkmann RE, Elstein NL (1998): Contraception with medroxyprogesterone may be beneficial. BMJ 316: 935
Klipping CH, Duijkers I, Trummer D, Marr J (2008) Supression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 76: (1): 102–107
Lätheenmäki P, Haukkamaa M, Puolakka J et al. (1998) Open randomized study of the use of levonorgestrel-releasing intrauterinesystem as alternative to hysterectomy. BMJ 316: 1122–1126
Lidegaard O, Kreiner S (2002) Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 65: 197–205
Marchbanks PA, McDonald JA, Wilson HG et al. (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346: 2025–2032
McKeage K, Croxtall JD (2011) Ulipristal acetate: a review of its use in emergency contraception. Drugs 71 (7): 935–945 [PubMed PMID: 21568368]
Mline RL, Knight JA, John EM et al. (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and RCA2 mutations. Cancer Epidemiol Biomarkers Prev 14: 350–356
Neumann F, Düsterberg B (1998) Entwicklung auf dem Gebiet der Gestagene. Reproduktionsmedizin 14: 257–264
Park BK, Kitteringham NR, Pirmohamed M, Tucker GT (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications, Br J Pharmacol 41: 477–491
Peterson HB, Jeng G, Folger SG, Hillis SA, Marchbanks PA, Wilcox LS (2000) The risk of menstrual abnormalities after tubal sterilization. N Engl J Med 343: 1681–1687
Piaggio G, von Hertzen H, Grimes DA, et al. (1999) Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task force on postovulatory methods of fertility regulation (letter). Lancet 353: 721
Rizk DE, Kumar RM (1996) Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuos oral contraceptive. Am J Hematol 52: 237–238
Rogoskaya S, Rivera R, Grimes DA et al. (2005) Effect of levonorgestrel- intrauterine system in women with type 1 diabetes: a randomized trial. Obstet Gynecol 105: 811–815
Roumen FJME, Apter D, Mulders TMT, Dieben TOM (2001) Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16: 469–475
Schaedel ZE, Dohen G, Powell MC (2005) The use of the levonorgestrel- releasing intrauterine-system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 193: 1361–1363
Schindler AE (2001) Die Bedeutung der Gestagene bei gut- und bösartigen Brusterkrankungen. Gynäkol Praxis 25: 35–44
Schindler AE (2007) Nichtkontrazeptive Anwendungsmöglichkeiten von hormonellen Kontrazeptiva. Frauenarzt 48, 7: 668–673
Schlesselman JJ (1991) Oral contraceptives and neoplasia of the uterine corpus. Contraception 43: 557–579
Schlesselman JJ (1995) Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 85: 793–801
Sillem M, Schneidereit R, Teichmann AT et al. (2003) Anwendung Drospirenon- haltigen Kontrazeptivums im Langzyklus. Frauenarzt 44: 876–881
Silvera SA, MillerAB, Rohan TE (2002) Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obsts Gynecol 186: 195–197
Silvera SA, Miller AB, Rohan TE (2005) Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 16 (9): 1059–1563 [PubMed PMID: 16184471]
Spitzer WO (1996) The future or oral contraceptives: research priorities. Hum Reprod 11: 688–689
Spitzer WO, Faith JM, MacRae KD (2002) Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Human Repruduction 17 (9): 2307–2314
Staupe G, Vieth L (1996) Die Pille – von der Lust und von der Liebe. Berlin: Rowohlt
Suissa S, Blais L, Spitzer WO, Cusson, J, Lewis M, Heinemann L (1997) First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56: 141–146
Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ (2000) Hormone withdrawalsymptoms in ral contraceptive users. Obstet Gynecol 95: 261–266
Teichmann AT (1997) Empfängnisverhütung. Stuttgart New York: Thieme
Timmer CJ, Mulders TMT (2000) Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 39: 233–242
Silvera SA, Miller AB, Rohan TE (2005) Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 16 (9): 1059–1563 [PubMed PMID: 16184471]
Vasilakis C, Jick H, del Mar Melero-Montes M (1999) Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354 (9190): 1610–1611 [PubMed PMID: 10560680]
Vasilakis C, Jick H, del Mar Melero-Montes M (1999) Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354 (9190): 1610–1611 [PubMed PMID: 10560680]
Von Hertzen H, Piaggio G, Van Look PF (1998) Task force on postovulatory methods of fertility regulation. Lancet 12; 352 (9144): 1939
Wallwiener et al. (Hrsg) (2008) Atlas der gynäkologischen Operationen, 7. Auf. [begründet von Hirsch HA, Käser O, Iklé FA (Hrsg)]. Stuttgart New York: Thieme
WHO (1998a) The World Health Organization Multinational Study of Breast-feeding and Lactational Amenorrhea. II. Factors associated with the length of amenorrhea. World Health Organization Task Force on Methods for the Natural Regulation of Fertility. Fertil Steril 70: 461471
WHO (1998b) The World Health Organization Multinational Study of Breast-feeding and Lactational Amenorrhea. I. Description of infant feeding patterns and of the return of menses. World Health Organization Task Force on Methods for the Natural Regulation of Fertility. Fertil Steril 70: 448–460
WHO (1999) The World Health Organization multinational study of breastfeeding and lactational amenorrhea. III. Pregnancy during breast-feeding. World Health Organization Task Force on Methods for the Natural Regulation of Fertility. Fertil Steril 72: 431– 440
Wiegratz I, Hommel HH, Zimmermann T, Kuhl H (2004) Attitude of German women and gynecologists toward long-cycle treatment with oral contraceptives. Contraception 69: 37–42
Wilson EW (1996) Sterilization. Baillere's Clin Obstet Gynaecol 10 (1): 103
Winkler UH, Schindler AE, Brinkmann OS et al. (2001) Cyclic progestin- therapy for the management of mastopathy on mastodynia. Gynecol Endocrinol 15 (Suppl 6): 637–643
Internetadressen
Bundesamt für gesundheitliche Aufklärung (BZgA): Informiertheit über den Bereich Empfängnisverhütung [www.forschung.sexualaufklaerung.de/2131.html]
Bundesamt für gesundheitliche Aufklärung (BZgA) (2011a) Ergebnisse der Repräsentativbefragung zum Verhütungsverhalten Erwachsener [www.forschung.sexualaufklaerung.de/4488.html]; Erste Ergebnisse unter [www.forschung.sexualaufklaerung.de/fileadmin/fileadmin-forschung/pdf/Hintergrundpapier_Verhuetung.pdf ]
Bundesamt für gesundheitliche Aufklärung (BZgA) (2011b) Repräsentative Wiederholungsbefragung von 14- bis 17-Jährigen und ihren Eltern: Jugendsexualität [www.forschung.sexualaufklaerung.de/4424.html]
Statistisches Bundesamt, Wiesbaden: 12. koordinierte Bevölkerungsvorausberechnung [www.destatis.de/bevoelkerungspyramide/]
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Amari, F., Beyer, D.A., Ludwig, M., Felberbaum, R.E., Weiss, J.M., Diedrich, K. (2013). Kontrazeption und Familienplanung. In: Kaufmann, M., Costa, S.D., Scharl, A. (eds) Die Gynäkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20923-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-20923-9_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20922-2
Online ISBN: 978-3-642-20923-9
eBook Packages: Medicine (German Language)